Avalo Therapeutics (NASDAQ:AVTX) Upgraded to “Hold” at Wall Street Zen

Avalo Therapeutics (NASDAQ:AVTX) was upgraded by stock analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a research note issued on Sunday.

Several other brokerages also recently issued reports on AVTX. Guggenheim assumed coverage on Avalo Therapeutics in a report on Monday, February 2nd. They set a “buy” rating and a $50.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Friday, January 9th. BTIG Research restated a “buy” rating and set a $40.00 target price on shares of Avalo Therapeutics in a research note on Tuesday, March 24th. HC Wainwright upped their price target on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Mizuho raised shares of Avalo Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $42.25.

Avalo Therapeutics Price Performance

AVTX stock opened at $13.89 on Friday. Avalo Therapeutics has a fifty-two week low of $3.39 and a fifty-two week high of $20.72. The stock has a market capitalization of $316.55 million, a P/E ratio of -2.42 and a beta of 0.84. The business has a 50-day moving average of $15.47 and a 200-day moving average of $15.81.

Avalo Therapeutics (NASDAQ:AVTX) last released its earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($1.54) by $1.17. The firm had revenue of $0.06 million during the quarter, compared to the consensus estimate of ($0.21) million. Equities analysts expect that Avalo Therapeutics will post -19.07 EPS for the current year.

Insider Buying and Selling

In other Avalo Therapeutics news, insider Mittie Doyle sold 25,492 shares of the company’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $16.15, for a total value of $411,695.80. Following the transaction, the insider directly owned 3,622 shares of the company’s stock, valued at $58,495.30. This represents a 87.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 3.03% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Avalo Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. BIT Capital GmbH bought a new stake in shares of Avalo Therapeutics in the third quarter valued at about $25,000. PFS Partners LLC grew its stake in shares of Avalo Therapeutics by 100.0% in the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after acquiring an additional 1,000 shares in the last quarter. Quadrature Capital Ltd bought a new position in Avalo Therapeutics during the second quarter worth about $55,000. Boothbay Fund Management LLC acquired a new stake in Avalo Therapeutics in the 2nd quarter worth about $56,000. Finally, Dimensional Fund Advisors LP acquired a new stake in Avalo Therapeutics in the 3rd quarter worth about $143,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.